These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The many vs. the few. Loewenstein G Hastings Cent Rep; 2012; 42(5):7-8; author reply 8-9. PubMed ID: 23050293 [No Abstract] [Full Text] [Related]
3. The many vs. the few. Wells RJ Hastings Cent Rep; 2012; 42(5):7; author reply 8-9. PubMed ID: 23050292 [No Abstract] [Full Text] [Related]
4. The many vs. the few. Menzel PT Hastings Cent Rep; 2012; 42(5):5-6; author reply 8-9. PubMed ID: 23050290 [No Abstract] [Full Text] [Related]
5. How should we model rare disease allocation decisions? London AJ Hastings Cent Rep; 2012; 42(1):3. PubMed ID: 22616383 [No Abstract] [Full Text] [Related]
6. Which orphans will find a home? The rule of rescue in resource allocation for rare diseases. Largent EA; Pearson SD Hastings Cent Rep; 2012; 42(1):27-34. PubMed ID: 22616398 [No Abstract] [Full Text] [Related]
7. The many vs. the few. McCabe C Hastings Cent Rep; 2012; 42(5):6-7; author reply 8-9. PubMed ID: 23050291 [No Abstract] [Full Text] [Related]
8. The many vs. the few. Zallen DT Hastings Cent Rep; 2012; 42(5):4-5; author reply 8-9. PubMed ID: 22976402 [No Abstract] [Full Text] [Related]
9. Reasonable disagreement about identified vs. statistical. Daniels N Hastings Cent Rep; 2012; 42(1):35-45. PubMed ID: 22616399 [No Abstract] [Full Text] [Related]
10. [Conference 1. An economic observatory for orphan drugs: myth or reality?]. Duguet C; Ferry A Med Sci (Paris); 2014 Apr; 30 Spe(1):21-3. PubMed ID: 24755173 [No Abstract] [Full Text] [Related]
11. Rationing of drugs for rare diseases. Hughes D Pharmacoeconomics; 2006; 24(4):315-6. PubMed ID: 16605277 [No Abstract] [Full Text] [Related]
12. Personal reflections of a patient representative in an appraisal committee. Smit C Patient; 2015 Feb; 8(1):5-10. PubMed ID: 25256116 [No Abstract] [Full Text] [Related]
13. Rare diseases and effective treatments: are we delivering? Luzzatto L; Hollak CE; Cox TM; Schieppati A; Licht C; Kääriäinen H; Merlini G; Schaefer F; Simoens S; Pani L; Garattini S; Remuzzi G Lancet; 2015 Feb; 385(9970):750-2. PubMed ID: 25752159 [No Abstract] [Full Text] [Related]
14. How can the risk that orphan drugs present to budgets be managed better? O'Neill C Clin Ther; 2010 Aug; 32(9):1640-1. PubMed ID: 20974321 [No Abstract] [Full Text] [Related]
15. Competing for public funding of medicines to treat rare disorders in New Zealand. Crausaz S Bull World Health Organ; 2015 Feb; 93(2):67. PubMed ID: 25883396 [No Abstract] [Full Text] [Related]
16. Why orphan drug coverage reimbursement decision-making needs patient and public involvement. Douglas CM; Wilcox E; Burgess M; Lynd LD Health Policy; 2015 May; 119(5):588-96. PubMed ID: 25641123 [TBL] [Abstract][Full Text] [Related]
17. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives. John JE Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052 [No Abstract] [Full Text] [Related]